Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Beigene Ltd Ads (BGNE)

Beigene Ltd Ads (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,894,178
  • Shares Outstanding, K 90,400
  • Annual Sales, $ 428,210 K
  • Annual Income, $ -948,630 K
  • 60-Month Beta 1.31
  • Price/Sales 59.42
  • Price/Cash Flow N/A
  • Price/Book 9.88
Trade BGNE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -4.11
  • Number of Estimates 3
  • High Estimate -4.06
  • Low Estimate -4.17
  • Prior Year -5.11
  • Growth Rate Est. (year over year) +19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
223.77 +26.87%
on 09/02/20
287.74 -1.33%
on 09/30/20
+47.60 (+20.14%)
since 09/01/20
3-Month
189.07 +50.16%
on 07/02/20
287.74 -1.33%
on 09/30/20
+94.72 (+50.07%)
since 07/01/20
52-Week
114.41 +148.14%
on 10/10/19
287.74 -1.33%
on 09/30/20
+164.42 (+137.61%)
since 10/01/19

Most Recent Stories

More News
All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BGNE : 284.30 (-0.75%)
4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

EBS : 104.42 (+1.05%)
HZNP : 80.78 (+3.99%)
RGEN : 149.63 (+1.42%)
BGNE : 284.30 (-0.75%)
BeiGene's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in BeiGene.

BGNE : 284.30 (-0.75%)
Clinical Data From Full Phase 1 Cohort of Investigational Sotorasib Published in New England Journal of Medicine

Clinical Data From Full Phase 1 Cohort of Investigational Sotorasib Published in New England Journal of Medicine

AMGN : 256.50 (+0.92%)
BGNE : 284.30 (-0.75%)
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

and , /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd., (Nasdaq:BGNE; HKEX: 06160), a...

BGNE : 284.30 (-0.75%)
LPTX : 1.9800 (unch)
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from...

BGNE : 284.30 (-0.75%)
BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will present...

BGNE : 284.30 (-0.75%)
MS : 47.98 (-0.77%)
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA(R) (zanubrutinib) in Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission...

BGNE : 284.30 (-0.75%)
BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the company's ordinary...

BGNE : 284.30 (-0.75%)
BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd., today announced that the companies have executed an exclusive license agreement for BeiGene to develop,...

BGNE : 284.30 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

2nd Resistance Point 292.20
1st Resistance Point 289.32
Last Price 284.30
1st Support Level 281.98
2nd Support Level 277.52

See More

52-Week High 287.74
Last Price 284.30
Fibonacci 61.8% 221.53
Fibonacci 50% 201.07
Fibonacci 38.2% 180.62
52-Week Low 114.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar